单次与多次分割放疗对转移性肿瘤椎管受压患者行走状态的影响:SCORAD随机临床试验
SCORAD多中心非劣效性随机试验纳入686例转移性肿瘤伴脊髓或马尾受压患者,比较单次8 Gy放疗与5次20 Gy放疗。
要点
- 单次8 Gy放疗在第8周行走状态未达到非劣效于5次20 Gy放疗的标准。
- 12周总生存率单次组50%对多次组55%,分层HR 1.02(95%CI 0.74-1.41)。
核心结论
- 在转移性实体瘤伴椎管受压患者中,单次8 Gy放疗相比5次20 Gy放疗未满足第8周行走状态非劣效性标准。
- 解释该发现临床重要性时应考虑置信区间下限与非劣效界值的重叠程度。
研究设计与样本
- 多中心非劣效性随机临床试验,在英国42个和澳大利亚5个放疗中心开展。
- 纳入686例转移性肿瘤伴脊髓或马尾受压、预期生存超过8周且未接受过同部位放疗的患者。
- 随机分为单次8 Gy外照射放疗组(n=345)和5次连续5天共20 Gy放疗组(n=341)。
主要发现
- 12周总生存率单次组50%、多次组55%,分层风险比1.02(95%CI 0.74-1.41)。
- 其他11个次要终点组间差异无统计学意义或未满足非劣效性标准。
关键数值与推荐
- 主要终点第8周行走状态基于4点量表,1级为无需辅助行走且肌力5/5,2级为使用辅助行走或肌力4/5。
- 非劣效性界值为行走状态差异-11%。
临床怎么用
- 单次8 Gy放疗不能常规替代5次20 Gy放疗用于维持转移性椎管受压患者第8周行走状态。
- 临床决策需结合置信区间下限与非劣效界值的重叠情况及患者个体情况综合判断。
局限性
- 686例随机患者中仅342例(49.8%)纳入主要终点分析,255例在第8周评估前死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Malignant spinal canal compression, a major complication of metastatic cancer, is managed with radiotherapy to maintain mobility and relieve pain, although there is no standard radiotherapy regimen. OBJECTIVE: To evaluate whether single-fraction radiotherapy is noninferior to 5 fractions of radiotherapy. DESIGN, SETTING, AND PARTICIPANTS: Multicenter noninferiority randomized clinical trial conducted in 42 UK and 5 Australian radiotherapy centers. Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area. Patients were recruited between February 2008 and April 2016, with final follow-up in September 2017. INTERVENTIONS: Patients were randomized to receive external beam single-fraction 8-Gy radiotherapy (n = 345) or 20 Gy of radiotherapy in 5 fractions over 5 consecutive days (n = 341). MAIN OUTCOMES AND MEASURES: The primary end point was ambulatory status at week 8, based on a 4-point scale and classified as grade 1 (ambulatory without the use of aids and grade 5 of 5 muscle power) or grade 2 (ambulatory using aids or grade 4 of 5 muscle power). The noninferiority margin for the difference in ambulatory status was -11%. Secondary end points included ambulatory status at weeks 1, 4, and 12 and overall survival. RESULTS: Among 686 randomized patients (median [interquartile range] age, 70 [64-77] years; 503 (73%) men; 44% had prostate cancer, 19% had lung cancer, and 12% had breast cancer), 342 (49.8%) were analyzed for the primary end point (255 patients died before the 8-week assessment). Ambulatory status grade 1 or 2 at week 8 was achieved by 115 of 166 (69.3%) patients in the single-fraction group vs 128 of 176 (72.7%) in the multifraction group (difference, -3.5% [1-sided 95% CI, -11.5% to ∞]; P value for noninferiority = .06). The difference in ambulatory status grade 1 or 2 in the single-fraction vs multifraction group was -0.4% (63.9% vs 64.3%; [1-sided 95% CI, -6.9 to ∞]; P value for noninferiority = .004) at week 1, -0.7% (66.8% vs 67.6%; [1-sided 95% CI, -8.1 to ∞]; P value for noninferiority = .01) at week 4, and 4.1% (71.8% vs 67.7%; [1-sided 95% CI, -4.6 to ∞]; P value for noninferiority = .002) at week 12. Overall survival rates at 12 weeks were 50% in the single-fraction group vs 55% in the multifraction group (stratified hazard ratio, 1.02 [95% CI, 0.74-1.41]). Of the 11 other secondary end points that were analyzed, the between-group differences were not statistically significant or did not meet noninferiority criterion. CONCLUSIONS AND RELEVANCE: Among patients with malignant metastatic solid tumors and spinal canal compression, a single radiotherapy dose, compared with a multifraction dose delivered over 5 days, did not meet the criterion for noninferiority for the primary outcome (ambulatory at 8 weeks). However, the extent to which the lower bound of the CI overlapped with the noninferiority margin should be considered when interpreting the clinical importance of this finding. TRIAL REGISTRATION: ISRCTN Identifiers: ISRCTN97555949 and ISRCTN97108008.
引用
- Hoskin PJ, Hopkins K, Misra V, et al. Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial. JAMA. 2019. PMID: 31794625. doi:10.1001/jama.2019.17913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。